Expert review of anticancer therapy
-
Expert Rev Anticancer Ther · Aug 2001
ReviewRituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
Rituximab (Rituxan) was the first monoclonal antibody approved for cancer therapy and the first single-agent approved for therapy of lymphoma. When combined with CHOP, rituximab is the only drug that has been shown to improve survival of a subpopulation of patients with diffuse large cell lymphoma during the last three decades. ⋯ Furthermore, it is currently being evaluated in several nonmalignant diseases, such as autoimmune disorders. This review will focus on the role of rituximab in patients with non-Hodgkin's lymphoma.